> Detailanzeige

Hennigs, André [Verfasser:in]; Riedel, Fabian [Verfasser:in]; Marmé, Frederik [Verfasser:in]; Sinn, Peter [Verfasser:in]; Lindel, Katja [Verfasser:in]; Gondos, Ádám [Verfasser:in]; Smetanay, Katharina [Verfasser:in]; Golatta, Michael [Verfasser:in]; Sohn, Christof [Verfasser:in]; Schütz, Florian [Verfasser:in]; Heil, Jörg [Verfasser:in]; Schneeweiss, Andreas [Verfasser:in]

Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade
  • Beteiligte: Hennigs, André [Verfasser:in]; Riedel, Fabian [Verfasser:in]; Marmé, Frederik [Verfasser:in]; Sinn, Peter [Verfasser:in]; Lindel, Katja [Verfasser:in]; Gondos, Ádám [Verfasser:in]; Smetanay, Katharina [Verfasser:in]; Golatta, Michael [Verfasser:in]; Sohn, Christof [Verfasser:in]; Schütz, Florian [Verfasser:in]; Heil, Jörg [Verfasser:in]; Schneeweiss, Andreas [Verfasser:in]
  • Erschienen: 15 October 2016
  • Erschienen in: Breast cancer research and treatment ; 160(2016), 3, Seite 491-499
  • Sprache: Englisch
  • DOI: 10.1007/s10549-016-4016-4
  • Identifikator:
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: BackgroundDuring the last decade, neoadjuvant chemotherapy (NACT) of early breast cancer (EBC) evolved from a therapy intended to enable operability to a standard treatment option aiming for increasing cure rates equivalent to adjuvant chemotherapy (ACT). In parallel, improvements in the quality control of breast cancer care have been established in specialized breast care units.Patients and methodsThis study analyzed chemotherapy usage in patients with EBC treated at the Heidelberg University Breast Unit between January 2003 and December 2014.ResultsOverall, 5703 patients were included in the analysis of whom 2222 (39 %) received chemotherapy, 817 (37 %) as NACT, and 1405 (63 %) as ACT. The chemotherapy usage declined from 48 % in 2003 to 34 % in 2014 of the cohort. Further, the proportion of NACT raised from 42 to 65 % irrespective of tumor subtype. In addition, frequency of pathologic complete response (pCR) defined as no tumor residues in breast and axilla (ypT0 ypN0) at surgery following NACT increased from 12 % in 2003 to 35 % in 2014. The greatest effect was observed in HER2+ breast cancer with an increase in patients achieving pCR from 24 to 68 %.ConclusionsThe results mirror the refined indication for chemotherapy in EBC and its preferred usage as NACT in Germany. The increase in pCR rate over time suggests improvement in outcome accomplished by a multidisciplinary decision-making process and stringent measures for quality control.
  • Zugangsstatus: Freier Zugang